WhiteSands Treatment Center Publishes New Resource on Cognitive Recovery After Stopping Gabapentin

Fort Myers, Florida - March 04, 2026 - PRESSADVANTAGE - WhiteSands Treatment Center has published a new educational ...

Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases

Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases.

ChatGPT's GPT-5.3 Instant May Show Fewer Links In Web Search Results

OpenAI announced GPT-5.3 Instant and said it "delivers more accurate answers, richer and better-contextualized results when searching the web, and reduces unnecessary dead ends, caveats, and overly ...

WhiteSands Treatment Center Publishes New Resource on Effexor Withdrawal Risks and Clinical Safety

Fort Myers, Florida - March 03, 2026 - PRESSADVANTAGE - WhiteSands Treatment Center has published a new educational ...